This review evaluates the role of Glivec in the treatment of chronic myelogenous leukemia and other malignant tumors. Preclinical and clinical evidence showed that Glivec demonstrated a potent and specific inhibition...This review evaluates the role of Glivec in the treatment of chronic myelogenous leukemia and other malignant tumors. Preclinical and clinical evidence showed that Glivec demonstrated a potent and specific inhibition on BCR-ABL positive leukemias and other malignant tumors in which overexpression of c-kit and PDGFR-b played a major role in their pathogenesis. Glivec has induced complete hematologic responses in up to 98% of patients evaluated in clinical trials. It's a very successful drug that supported the idea of targeted therapy through inhibition of tyrosine kinases. Although it's still in the early stages of clinical development and the resistance to Glivec remains to be a problem needed further study, a great deal has been learned from these research and observation. And with the increasing data, molecular targeting therapy will play much more important role in the treatment of malignant tumors. With the better understanding of the pathogenesis of malignant tumors, well-designed drugs targeting the specific molecular abnormalities with higher efficacy and lower side effect will benefit numerous patients with malignant tumors.展开更多
目的:观察在体外环境中使用ICCs(Interstitial cells of Cajal,ICCs)样细胞表面c-kit受体抑制剂Glivec后,豚鼠逼尿肌自主收缩活动的变化,探讨逼尿肌中ICCs样细胞的作用。方法:制作豚鼠膀胱逼尿肌肌条,并在Kreb液中孵育,在体外环境中添加...目的:观察在体外环境中使用ICCs(Interstitial cells of Cajal,ICCs)样细胞表面c-kit受体抑制剂Glivec后,豚鼠逼尿肌自主收缩活动的变化,探讨逼尿肌中ICCs样细胞的作用。方法:制作豚鼠膀胱逼尿肌肌条,并在Kreb液中孵育,在体外环境中添加c-kit受体抑制剂Glivec,通过张力换能器输入生理记录仪记录逼尿肌肌条自主收缩活动的变化。结果:与对照组比较,不同剂量Glivec孵育逼尿肌肌条后,逼尿肌肌条收缩幅度明显下降(100μmol/L:547.87±43.00mg,p<0.01,n=15;300μmol/L:197.47±39.20mg,p<0.01,n=15),逼尿肌肌条收缩频率也明显下降(100μmol/L:2.44±0.16次/分,p<0.05,n=15;300μmol/L:1.11±0.17次/分,p<0.01,n=15)。结论:ICCs样细胞在逼尿肌自发收缩中可能充当起搏细胞的角色。展开更多
基金This work was supported by a grant from Nanjing Science & Technology Foundation.
文摘This review evaluates the role of Glivec in the treatment of chronic myelogenous leukemia and other malignant tumors. Preclinical and clinical evidence showed that Glivec demonstrated a potent and specific inhibition on BCR-ABL positive leukemias and other malignant tumors in which overexpression of c-kit and PDGFR-b played a major role in their pathogenesis. Glivec has induced complete hematologic responses in up to 98% of patients evaluated in clinical trials. It's a very successful drug that supported the idea of targeted therapy through inhibition of tyrosine kinases. Although it's still in the early stages of clinical development and the resistance to Glivec remains to be a problem needed further study, a great deal has been learned from these research and observation. And with the increasing data, molecular targeting therapy will play much more important role in the treatment of malignant tumors. With the better understanding of the pathogenesis of malignant tumors, well-designed drugs targeting the specific molecular abnormalities with higher efficacy and lower side effect will benefit numerous patients with malignant tumors.
文摘目的:观察在体外环境中使用ICCs(Interstitial cells of Cajal,ICCs)样细胞表面c-kit受体抑制剂Glivec后,豚鼠逼尿肌自主收缩活动的变化,探讨逼尿肌中ICCs样细胞的作用。方法:制作豚鼠膀胱逼尿肌肌条,并在Kreb液中孵育,在体外环境中添加c-kit受体抑制剂Glivec,通过张力换能器输入生理记录仪记录逼尿肌肌条自主收缩活动的变化。结果:与对照组比较,不同剂量Glivec孵育逼尿肌肌条后,逼尿肌肌条收缩幅度明显下降(100μmol/L:547.87±43.00mg,p<0.01,n=15;300μmol/L:197.47±39.20mg,p<0.01,n=15),逼尿肌肌条收缩频率也明显下降(100μmol/L:2.44±0.16次/分,p<0.05,n=15;300μmol/L:1.11±0.17次/分,p<0.01,n=15)。结论:ICCs样细胞在逼尿肌自发收缩中可能充当起搏细胞的角色。
